GlassScriptPhysician profile
Lucyamma Thalody
NPI 1790892941
$929.34
in general payments reported to CMS, 2019-2025
24 companies · $32.64 in 2025
The $32.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $84.51 · 2021: $118 · 2022: $53.38 · 2023: $36.14 · 2024: $47.48 · 2025: $32.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $116.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $162.71 | 2019-2020 | |
| Optinose US, INC. | $97.85 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $71.39 | 2019-2022 | |
| Glaxosmithkline, LLC. | $66.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.01 | 2019-2022 | |
| Abbott Laboratories | $48.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.10 | 2019-2020 | |
| Gilead Sciences, INC. | $30.70 | 2022-2025 | |
| Astellas Pharma US INC | $28.97 | 2019-2020 | |
| Amgen INC. | $27.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.62 | 2019 | |
| Novo Nordisk INC | $25.08 | 2019 | |
| Dexcom, INC. | $17.24 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.99 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.77 | 2023 | Gvoke Hypopen |
| Mannkind Corporation | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.94 | 2021 | |
| Hikma Pharmaceuticals USA | $14.32 | 2020 | |
| Mylan Specialty L.P. | $12.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.45 | 2019 | |
| Phadia US INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucyamma Thalody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.